Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

V5514

Sigma-Aldrich

Anti-Vasopressin V2 Receptor antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

MDL-Nummer:
MFCD06798554
UNSPSC-Code:
12352203
NACRES:
NA.41

Biologische Quelle

rabbit

Qualitätsniveau

200

Konjugat

unconjugated

Antikörperform

affinity isolated antibody

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Form

buffered aqueous solution

Speziesreaktivität

human

Methode(n)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 3 μg/mL using human kidney

UniProt-Hinterlegungsnummer

P30518

Versandbedingung

dry ice

Lagertemp.

−20°C

Angaben zum Gen

human ... AVPR2(554)
mouse ... Avpr2(12000)
rat ... Avpr2(25108)

Immunogen

Synthetic peptide corresponding to the N-termal extracellular domain of human vasopressin V2 receptor. The immunizing peptide has 67% homology with the rat and mouse gene.

Anwendung

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunohistochemistry (1 paper)

Biochem./physiol. Wirkung

Vasopressin V2 receptor is a G-protein-coupled receptor that binds to the peptide hormone arginine vasopressin produced by posterior pituitary gland. The V2 receptor stimulates the production of cyclic AMP, controls the water reabsorption and salt balance by the kidneys. Antagonists to the V2 receptor have applications in the treatment of congestive heart failure, hypertension, hyponatremia and excessive water retention.

Physikalische Form

Solution in phosphate buffered saline containing 0.1% sodium azide.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

nwg

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Juan Garona et al.
Clinical & experimental metastasis, 33(6), 589-600 (2016-05-06)
[V(4)Q(5)]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V(4)Q(5)]dDAVP inhibits angiogenesis and metastatic progression
Abeda Jamadar et al.
International journal of molecular sciences, 23(14) (2022-07-28)
Vasopressin type-2 receptor (V2R) is ectopically expressed and plays a pathogenic role in clear cell renal cell carcinoma (ccRCC) tumor cells. Here we examined how V2R signaling within human ccRCC tumor cells (Caki1 cells) stimulates stromal cancer-associated fibroblasts (CAFs). We
Shuai Mu et al.
Molecules (Basel, Switzerland), 19(2), 2694-2706 (2014-02-26)
Twenty-one non-peptide substituted desloratadine class compounds were synthesized as novel arginine vasopressin receptor antagonists from desloratadine via successive acylation, reduction and acylation reactions. Their structures were characterized by 1H-NMR and HRMS, their biological activity was evaluated by in vitro and
Natasha Tatiana Sobol et al.
Experimental and therapeutic medicine, 21(6), 566-566 (2021-04-15)
Osteosarcoma is the most prevalent primary bone malignancy. Due to its high aggressiveness, novel treatment strategies are urgently required to improve survival of patients with osteosarcoma, especially those with advanced disease. Desmopressin (dDAVP) is a widely used blood-saving agent that
[Human recombinant alpha-2b interferon (Introna). Intralesional treatment of therapy-resistant condylomata acuminata].
C S Petersen et al.
Ugeskrift for laeger, 149(24), 1594-1595 (1987-06-08)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.